Autopsy report · NCT00060996
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
Cause of deathNo reason given
Life of this trial
- Registered 3 months after it had already started.
- Ran for about 1 year 7 months before it stopped.
- 30 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- United Therapeutics
- Sponsor type
- Industry
- Conditions
- Critical Limb Ischemia; Peripheral Vascular Disease; Foot Ulcers; Rest Leg Pain
- Interventions
- Remodulin® (treprostinil sodium) Injection
- Participants
- 30
- Sites
- 7
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.